Cite

HARVARD Citation

    Dasanu, C. et al. (2019). Inferior outcomes in immunocompromised Merkel cell carcinoma patients: Can they be overcome by the use of PD1/PDL1 inhibitors?. Journal of oncology pharmacy practice. pp. 214-216. [Online]. 
  
Back to record